Pfizer's Lorbrena Shows Breakthrough Results in Advanced Lung Cancer Trials
TL;DR
Pfizer's drug Lorbrena significantly extends the life expectancy of patients with ALK-positive non-small cell lung cancer, a rare and particularly deadly form of the disease. New research shows that 60% of patients treated with Lorbrena were still alive after five years, compared to 8% of those treated with crizotinib. Lorbrena also effectively prevents brain metastasis, a common and severe complication of ALK-positive lung cancer. However, the drug may cause more neurotoxic side effects, which can be managed by adjusting the dosage.
- Lung cancer treatment: Pfizer's Lorbrena extends life in some non-small cell lung cancers NBC News
- Pfizer's drug for advanced lung cancer shows promising long-term trial results CNBC
- Pfizer's LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression Yahoo Finance
- Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data Reuters
- Trial results for new lung cancer drug are ‘off the charts’, say doctors The Guardian
Want the full story? Read the original reporting
Read on NBC News